BiotechTube

LCZ696 + Enalapril + Placebo to LCZ696 + Placebo to Enalapril

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heart Failure With Reduced Ejection Fraction (HF-rEF)

Conditions

Heart Failure With Reduced Ejection Fraction (HF-rEF)

Trial Timeline

Jun 15, 2015 → Feb 18, 2021

NCT ID
NCT02468232

About LCZ696 + Enalapril + Placebo to LCZ696 + Placebo to Enalapril

LCZ696 + Enalapril + Placebo to LCZ696 + Placebo to Enalapril is a phase 3 stage product being developed by Novartis for Heart Failure With Reduced Ejection Fraction (HF-rEF). The current trial status is completed. This product is registered under clinical trial identifier NCT02468232. Target conditions include Heart Failure With Reduced Ejection Fraction (HF-rEF).

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure With Reduced Ejection Fraction (HF-rEF) were approved

Approved (20) Terminated (2) Active (0)
✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
✅ConivaptanAstellas PharmaApproved
✅RegadenosonAstellas PharmaApproved
✅Regadenoson + GadoliniumAstellas PharmaApproved
✅regadenosonAstellas PharmaApproved
✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02468232Phase 3Completed

Competing Products

20 competing products in Heart Failure With Reduced Ejection Fraction (HF-rEF)

See all competitors
ProductCompanyStageHype Score
mRNA-0184ModernaPhase 1
0
IV diureticNuwellisPre-clinical
16
IV Loop DiureticsNuwellisPre-clinical
23
Stepped pharmacologic careNuwellisPhase 3
30
IV Loop Diuretics (LD)NuwellisPre-clinical
8
TRV120027 + Normal SalineTrevenaPhase 1
19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
TRV120027 + PlaceboTrevenaPhase 1/2
22
Ilofotase alfa + PlaceboAM-PharmaPhase 2
25
INXN-4001PrecigenPhase 1
23
LY3461767 + PlaceboEli LillyPhase 1
29
SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved
43
Pactimibe, CS-505Daiichi SankyoPhase 2
35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved
43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetilDaiichi SankyoPhase 3
32
OlmesartanDaiichi SankyoPhase 3
40
Carperitide + PlaceboDaiichi SankyoPhase 2
35
EdoxabanDaiichi SankyoPre-clinical
22
RegadenosonAstellas PharmaPhase 1
29
Advagraf + PrografAstellas PharmaPhase 2
35